Current Oncology Reports

, Volume 15, Issue 5, pp 433–435

Ovarian Cancer Survival: Steady Improvement, Despite Rhetoric to the Contrary

Invited Commentary

References

  1. 1.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006;24:988–94.PubMedCrossRefGoogle Scholar
  3. 3.
    Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3-weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet. 2009;374:1331–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312–22.PubMedGoogle Scholar
  5. 5.
    Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.PubMedCrossRefGoogle Scholar
  8. 8.
    Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–707.PubMedCrossRefGoogle Scholar
  9. 9.
    Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107–14.PubMedCrossRefGoogle Scholar
  11. 11.
    Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.PubMedCrossRefGoogle Scholar
  13. 13.
    Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009;114:195–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Du Bois A, et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Proc Am Soc Clin Oncol. 2013;LBA5503.Google Scholar
  16. 16.
    Vergote I, Finkler N, del Camop J, et al. Phase 3 randomized study of canfosfamide versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or –resistant ovarian cancer. Eur J Cancer. 2009;45:2324–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Markman M. Viewing ovarian cancer as a “chronic disease”: what exactly does this mean? Gynecol Oncol. 2006;100:229–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist. 2000;5:26–35.PubMedCrossRefGoogle Scholar
  19. 19.
    Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Landrum LM, Java J, Matthews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;130:12–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Coleman RL, Gershenson DM. Ovarian cancer. In: Rodriguez MA, Walters RS, Burke TW, editors. 60 years of survival outcomes at the University of Texas MD Anderson Cancer Center. New York: Springer; 2013. p. 85–96.CrossRefGoogle Scholar
  22. 22.

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Cancer Treatment Centers of AmericaPhiladelphiaUSA
  2. 2.Drexel University College of MedicinePhiladelphiaUSA

Personalised recommendations